Symposium Menu

HTRS 2023 Home

Welcome

Schedule of Events

Faculty

Call for Abstracts

Registration

Hotel Information

Continuing Education

Travel Awards

Member Recognition Awards

Sponsor & Exhibitor Opportunities

General Information

We highly encourage you to join the HTRS mailing list to stay up-to-date on the latest HTRS 2023 news.

Email [email protected] to be added to our list.
 

 Continuing Education

 


The HTRS 2023 Scientific Symposium welcomes all medical, advanced practice providers, and research professionals interested in disorders of hemostasis and thrombosis. Continuing education credits are provided for physicians, nurses, and pharmacists via the Postgraduate Institute for Medicine.

 


 Instructions to Receive Credits

Following the conference, an email with the application link will be sent to all attendees to apply for CE credits.

If you need your CE application information resent, email [email protected]. 


 Educational Objectives

Open AllClose All
  Learning Objective for Session 1-A Radio HTRS: Basic Science “Science Friday”

At the close of this session, attendees will be able to:

  • Identify new discoveries and “hot topics” in the areas of hemostasis, platelet biology, and thrombosis and vascular biology
  • Explain new findings emanating from discovery-based studies
  • Evaluate the potential impact of newly described findings on the existing knowledge of underlying biology, biochemistry, and cell biology of hemostasis and thrombosis
  Learning Objective for Session 1-B Radio HTRS: Clinical Science “Wait Up, HTRS - Not My Consult”

At the close of this session, attendees will be able to:

  • Identify and feel more comfortable advising patients with VTE on participation in contact sports that put them at risk for bleeding if they are on anticoagulation
  • Discuss the concept of a personalized pharmacokinetic/pharmacodynamic DOAC study, “safe” residual anticoagulation blood levels, and return-to-play decision making
  • Evaluate an intermittent anticoagulation strategy in non-elite and high-level athletes engaged in contact sports
  Learning Objective for Session 1-C Radio HTRS: Translational Science “All Things Considered”

At the close of this session, attendees will be able to:

  • Discuss VTE biomarkers that have clinical relevance
  • Identify steps required for actionable clinical translation of VTE biomarkers
  • Discuss and evaluate the ideal gene therapy delivery system for hemophilia A and B
  Learning Objective for Session 2-A HT at the Bedside and Bench: “Sticks and Stones: Hemophilia and Bone Health”

At the close of this session, attendees will be able to:

  • Discuss bone health and clinical relevance to people with hemophilia
  • Identify screening recommendations for bone health in people with hemophilia
  • Discuss treatment recommendations for people with hemophilia and decreased bone 
  Learning Objective for Session 2-B HT at the Bedside and Bench: “How I Treat/Manage: Bridging Science to Clinical Care”

At the close of this session, attendees will be able to:

  • Discuss the risk of thrombosis and its evaluation among transgender individuals
  • Evaluate the Use of Direct Oral Anticoagulants in Pediatrics 
  Learning Objective for Session 2-C HT at the Bedside and Bench: "Omics" Boot Camp

At the close of this session, attendees will be able to:

  • Describe current efforts to use “omics” research strategies to advance understanding of hemostasis and thrombosis
  • Discuss major findings from recent “omics” studies and their impact on knowledge of genes and proteins involved in hemostasis and thrombosis
  • Evaluate the relative advantages and disadvantages of different “omics” approaches
  Learning Objective for Session 3 Plenary: “Do We Dare to DOAC?”

At the close of this session, attendees will be able to:

  • Evaluate risks and benefits of DOACs vs warfarin in double positive APS patients
  • Describe settings in which DOACs are a reasonable alternative to warfarin in APS
  • Compare the efficacy of DOACs to warfarin for prevention of arterial thrombosis in APS
  Learning Objective for Session 4 Plenary: “VWF Biology”

At the close of this session, attendees will be able to:

  • Describe new developments in von Willebrand Disease management
  • Discuss VWF as a target in acquired VWF disease
  • Evaluate VWF levels and processing in health and disease
  Learning Objective for Session 5 State-of-the-Art-Lecture: "VITT"

At the close of this session, attendees will be able to:

  • Discuss the pathophysiology and mechanisms of vaccine-induced immune thrombotic thrombocytopenia (VITT) 
  • Explain how VITT is similar to and differs from heparin-induced thrombocytopenia (HIT)
  • Discuss treatment recommendations for people with VITT 
  Learning Objective for Session 6 Oral Abstract Presentations

At the close of these sessions, attendees will be able to discuss emerging topics and research in the field of hemostasis and thrombosis, based on submitted abstracts.

  Learning Objective for Session 7-A Hemostasis and Thrombosis in Special Populations: “Pregnancy”

At the close of this session, attendees will be able to:

  • Describe at least 2 dosing approaches to LMWH in pregnancy
  • Explain the role of TXA in preventing PPH
  • Discuss the risks and benefits of transitioning from DOAC to LMWH before vs after positive pregnancy test
  Learning Objective for Session 7-B Hemostasis and Thrombosis in Special Populations: “Sickle Cell Disease”

At the close of this session, attendees will be able to:

  • Discuss hormone use and its association with thrombosis in Sickle cell disease 
  • Describe and differentiate processes of venous clot formation in Sickle cell disease 
  • Discuss prevention of thrombosis in Sickle cell disease 
  Learning Objective for Session 7-C Hemostasis and Thrombosis in Special Populations: “Pediatrics”

At the close of this session, attendees will be able to:

  • Discuss challenges and pre-analytical variables of laboratory monitoring in ECMO, and different anticoagulants utilized in cancer-associated thrombosis
  • Explore different anticoagulants utilized in ECMO and strategies of anticoagulation with thrombocytopenia, and challenges with concurrent emicizumab and ITI 
  • Focus on bivalirudin advantages and challenges compared to heparin
  Learning Objective for Session 8 Oral Abstract Presentations

At the close of these sessions, attendees will be able to discuss emerging topics and research in the field of hemostasis and thrombosis, based on submitted abstracts.

  Learning Objective for Session 9 Speed Poster Session and In-Person Presentations

At the close of these sessions, attendees will be able to discuss emerging topics and research in the field of hemostasis and thrombosis, based on submitted abstracts.

  Learning Objective for Session 10-A Bench, Clinic, and Everything In Between: “Connecting Megakaryocyte and Platelet Biology to the Clinic”

At the close of this session, attendees will be able to:

  • Describe the process of platelet production from their precursor cells in the bone marrow
  • Explain how platelet and megakaryocyte research is guiding clinical diagnosis of bleeding and thrombotic disorders
  • Evaluate common platelet disorders based on aberrant platelet and megakaryocyte phenotypes
  Learning Objective for Session 10-B Bench, Clinic, and Everything In Between: “Trauma Induced Coagulopathy: Mechanisms and Management”

At the close of this session, attendees will be able to:

  • Identify major barriers to effectively treating trauma-induced coagulopathy
  • Explain mechanisms of endothelial dysfunction after trauma
  • Evaluate multiple blood product different treatment options post-trauma and their pros and cons for patient morbidity and mortality


 Additional Information

Faculty

See the​​​​​ Faculty page for a faculty list with complete titles, affiliations, and biographies. 
 

Program Agenda

See the Schedule of Events page for detailed daily agendas. 
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and HTRS. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of credits to be determined. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Continuing Nursing Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of credits to be determined. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
 

Continuing Pharmacy Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of credits of the Accreditation Council for Pharmacy Education to be determined. 
 

Policy on Privacy and Confidentiality

Please see the final activity for the policy on privacy and confidentiality that relates to this internet activity. More information can be found on the General Information page.
 

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest or a commercial interest.

 


Questions about HTRS 2023?

Email [email protected]

top